Get started

Stocksignals

What America Does with Its Money ? 🇺🇸 Decoding America's Spending: A Deep Dive into Government Finances This topic has been on the horizon for a while, and I think many new traders will be pleased to see it so LFG Just like a business, the government has its own financial records : 💰 Money comes in (primarily from taxes) 💸 Money goes out (to fund a variety of programs) With an expected gross domestic product (GDP) of nearly $29 trillion in 2024, the US remains the world’s largest economy, surpassing China’s $18.5 trillion. However, the US government isn’t exactly profitable. In fact, it’s been consistently running a growing deficit, raising concerns about its long-term financial stability. As a general election approaches, it's more important than ever to understand how the US generates and spends its money. So, let’s dive into the details Here’s a quick overview: - Revenue: A deep dive into taxes - Spending: Powering the nation - Bottom Line: Operating costs & the deficit - National Debt: A mounting challenge - The Future: America's financial outlook 1. Revenue: A Deep Dive into Taxes The US government operates on an enormous scale, and like any large organization, it requires a consistent stream of income to stay functional. However, unlike businesses that sell products or services, the government generates revenue primarily through taxes and fees In fiscal year 2023, the federal government collected an astounding $4.4 trillion So, where does all of this money come from? Let’s take a closer look: 👥 Individual Income Taxes:Nearly 50% of the government’s total revenue comes from individuals. Every time you receive a paycheck, a portion is automatically sent to Uncle Sam. This also includes taxes on capital gains from investments. 🏦 Social Security and Medicare Taxes: About 36% of revenue is generated from these taxes, which support programs like Social Security and Medicare for retirees and older adults. It’s a system where current workers help fund benefits for those who have already retired. 🏢 Corporate Income Taxes:Around 10% of the total revenue comes from businesses, which contribute a portion of their profits to the federal government. This is reflected in the income tax provisions that companies report. 🧩 Other Revenue:The remaining ~4% is sourced from various channels such as excise taxes (extra charges on goods like alcohol and tobacco), estate taxes, customs duties, and even fees collected from national park visits. 2. Spending: Powering the Nation Now that we’ve seen how money flows into the US Treasury, it’s time to explore the exciting part figuring out how it’s spent. The US government faces the enormous responsibility of keeping the country functioning, covering everything from national defense to healthcare and infrastructure. And that demands a massive amount of spending In fiscal year 2023, the federal government's net cost was $7.9 trillion, which is almost as large as the combined GDP of Germany and Japan the world’s third and fourth largest economies! -Outlays vs. Net Cost:In FY23, total outlays (the actual cash spent) reached $6.1 trillion. Outlays refer to the cash disbursements, while the net cost also includes accrual-based accounting adjustments, such as changes in the future value of federal employee retirement benefits. Who’s Deciding Where the Money Goes So, how does the government determine how to allocate all this money? It’s a balancing act involving both the President and Congress: -The President’s Proposal: The President begins the process by proposing a budget, outlining spending priorities based on requests from federal agencies. Think of it as a wish list—with a lot of extra zeros. -House and Senate Role:Next, the House and Senate Budget Committees take over. They review the President’s proposal, make adjustments, and ultimately create the final spending bills. This process involves hearings, debates, and a fair amount of political negotiation. Types of Spending -Mandatory Spending:These are legally required expenses, like Social Security and Medicare, which make up a significant portion of the budget. These costs rise over time, particularly as the population ages -Discretionary Spending:This is the part of the budget where the President and Congress decide how much to allocate to areas like defense, education, and more. In FY23, discretionary spending accounted for roughly 28% of total outlays, and it involves a yearly struggle as various departments compete for funding. -Supplemental Spending: In cases of emergency, Congress can pass additional funding outside the normal budget cycle, as it did for the COVID-19 pandemic in 2020. Where the Money Goes Now, let's dive deeper into the specific areas where all that spending is directed: -🏥 Healthcare Heavyweight:The Department of Health and Human Services commands the largest portion of spending, making up 22% of the net cost. This reflects the huge outlays for healthcare programs like Medicare and Medicaid. -👵 Social Safety Net:Programs like Veterans Affairs and the Social Security Administration also require significant funding, together accounting for 18% of the budget. This demonstrates the high priority placed on supporting veterans and retirees. -🫡 Defense and Security:The Department of Defense, tasked with ensuring national security, takes up 13% of government spending! -💸 The Interest Burden: A growing share of the budget is going toward paying interest on the national debt, consuming 9% of total spending. In FY23, government outlays represented 22% of the US economy (GDP). Over the past decade, this figure has remained slightly above 20%, excluding the exceptional impact of the COVID-19 pandemic. 3. Bottom Line: Operating Cost & Deficit When government expenditures exceed its revenue, a budget deficit occurs In FY23, the U.S. government recorded a $1.7 trillion deficit (revenue minus outlays). Here’s a breakdown of two key financial terms: -Net Operating Cost:This includes all costs incurred by the government, even if the payments haven’t been made yet. In FY23, the net operating cost was $3.4 trillion -Budget Deficit:This is a narrower measure, focusing only on the cash difference between revenue and outlays. As mentioned, the FY23 budget deficit stood at $1.7 trillion Both of these financial measures reveal a government consistently spending beyond its means—a pattern that has persisted for decades. In fact, over the past 50 years, the U.S. federal budget has only seen a surplus four times, with the most recent one occurring in 2001. 4. National Debt: A Mounting Challenge So, how does the government continue operating despite being in the red? It borrows money, mainly by issuing Treasury bonds, bills, and other securities. This borrowing adds to the national debt, which has grown into a major concern for the country’s economic outlook. As of September 2024, the national debt has reached a staggering $36 trillion. To put that in perspective, it's as if every person in the US owes over $100,000! Every time the government spends more than it earns, the shortfall is added to the national debt, which, in turn, increases the interest payments that need to be made in the future. Why the Debt Keeps Growing ? Several factors contribute to the relentless increase of the national debt: -Persistent Deficits:For decades, the government has continuously spent more than it collects in revenue, leading to ongoing debt accumulation. -Wars and Economic Crises: Significant events such as wars (like those in Iraq and Afghanistan) and economic crises (including the 2008 recession and the COVID-19 pandemic) often necessitate large government expenditures, further escalating the debt. -Tax Cuts and Spending Increases: Policy decisions that either reduce government revenue (through tax cuts) or increase spending (by introducing new programs or expanding existing ones) also play a role in growing the debt. The national debt presents a complicated issue without straightforward solutions. It requires balancing essential funding for programs and services while ensuring the nation’s long-term financial health. 5. The Future: America’s Finances The road ahead is filled with challenges. The national debt continues to rise, with a debt-to-GDP ratio surpassing 100%, raising concerns about the nation's long-term economic stability and ability to fulfill financial commitments. According to the Department of the Treasury, the current fiscal trajectory is unsustainable. Projections based on existing policies show a persistent gap between expected revenue and spending. Without substantial policy reforms, the national debt is likely to keep increasing. Several factors will influence the future of America’s finances: -Economic Growth: A strong economy generates higher tax revenues, making it easier to manage the debt. Conversely, slower growth could worsen the deficit and increase the debt burden. -Interest Rates:Rising interest rates would elevate the cost of servicing the national debt, redirecting funds from other vital programs. -Inflation: Excessive government debt can contribute to inflation, diminishing the purchasing power of individuals and businesses. -Political Polarization: The significant partisan divide in U.S. politics complicates consensus-building on fiscal policy and the implementation of long-term solutions to address the debt. -Demographic Shifts: An aging population increases pressure on entitlement programs like Social Security and Medicare, leading to higher government spending and potentially widening the deficit. To tackle the challenges of growing debt and deficits, a combination of strategies is needed: -Controlling Spending:Identifying areas for budget cuts or finding more efficient methods to deliver government services. -Increasing Revenue:Exploring avenues for raising revenue through tax reforms or other means. -Fostering Economic Growth:Implementing policies that promote sustainable long-term economic growth and boost tax revenues. -Encouraging Bipartisan Cooperation:Seeking common ground across party lines to implement lasting fiscal reforms. The future of America’s finances remains uncertain, but one thing is clear: addressing the national debt and ensuring the nation’s long-term fiscal health will require tough decisions and a commitment to responsible financial management. What Can Be Done? It’s easy to feel overwhelmed by the scale of these challenges, but meaningful change often starts with informed citizens. As we head into a new election cycle, understanding how the US government manages its finances is more crucial than ever. So, what do you think should be America’s financial priorities? Should policymakers concentrate on cutting spending, raising taxes, or fostering economic growth?
TVC:DXYEducation
by moonypto
2
How To Pick Top Pharma Stocks like a ProAnalyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is quite challenging sometimes also it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators In this article you will learn how to pick Top Pharma stocks like a pro trader and which factors you should consider, so buckle up 1/ Recognizing the risks At the very beginning, an investor you must recognize that the pharmaceutical industry is highly competitive, where a company's investment attractiveness depends not only on the rate of expansion of its portfolio of product candidates, revenue growth, margins, the amount of total debt and cash on the balance sheet but is also heavily influenced by the expiration of patents on medications and vaccines. Moreover, in recent months, the healthcare sector has increasingly felt the impact of the upcoming 2024 US presidential elections, as some politicians are aiming to further tighten regulation of drug prices despite the existing Inflation Reduction Act. 2/ Leveraging data to your advantage The second step use data wisely, you should check all kinda data including stock screener, transcripts of earnings calls, financial results for the last quarters, analyst expectations, options data... The goal is to filter companies in poor financial condition, as well as those that trade at a significant premium to the sector and/or competitors I would also like to point out that in the current market environment, with Fed interest rates remaining at multi year highs, I do not recommend investing in companies with market caps below $500 million, as they typically have limited cash reserves and weaker institutional backing Also, I'd recommend investors read 10-Ks and 10-Qs, especially the section related to debt and sources of financing of the company's operations, to reduce the likelihood of an "unexpected" drop in the share price. A striking example is Invitae Corporation aka NVTAQ which declared bankruptcy in mid February 2024! Was there a prerequisite for this? The answer is yes since the company continued to generate negative cash flow and also had convertible senior notes maturing in 2028. Convertible notes can involve significant financial risks if the company cannot effectively use the cash to grow the business and break even. In this case, management will not be able to pay off the bonds with cash reserves and will have to resort to significant dilution of investors. In my opinion, Pacific Biosciences of California, Inc. NASDAQ:PACB may face this problem because it has convertible senior notes maturing in 2028 and 2030. Factors that concern me include the company's declining revenue and total cash and short-term investments in recent quarters, while its operating expenses remain extremely high at around $80 million per quarter. Let's return to the second step in my approach to selecting the most promising assets in the healthcare sector. When selecting companies with market caps between $4 billion and $40 billion, I use more parameters since most of them already have FDA approved drugs and/or vaccines. As a result, it is also necessary to consider the rate of growth of operating income, net debt/EBITDA ratio, and how management copes with increased marketing and production costs. Finally, let's move on to the last basket, which contains pharmaceutical companies with market capitalizations exceeding $40 billion. I think, this group is best suited for more conservative investors looking for assets offering attractive dividend yields and growing net income, supported by a rich portfolio of FDA approved and experimental drugs. So, from Big Pharma, I like Pfizer Inc NYSE:PFE , AbbVie Inc NYSE:ABBV , Merck & Co NYSE:MRK and AstraZeneca PLC NASDAQ:AZN . I also want to include Novartis AG NYSE:NVS and Roche Holding AG OTC:RHHBY in this group sometimes investors need to make exceptions, namely if one larger company buys out a smaller player and/or when a major partnership agreement is concluded, as was the case between Merck and Daiichi Sankyo Company, Limited OTC:DSKYF in 2023. Also, in the event of a major acquisition or merger, the company's debt may temporarily increase sharply. If its management has previously implemented effective R&D and financial policies, the "net debt/EBITDA ratio" A remarkable example of a company falling into the "value trap" is Takeda Pharmaceutical Company Limited NYSE:TAK , which overpaid for Shire. This deal did not significantly strengthen or rejuvenate the Japanese company's portfolio of drugs. As a result, it had to sell off billions of dollars in assets to pay off its debt partially. However, despite all the efforts of Takeda's management, its net debt/EBITDA ratio, although it fell below 5x, remains high, namely about 4.7x at the end of March 2024. 3/ Identifying promising therapeutic areas In general, the more prevalent a disease is, the larger the total addressable market for a drug and, as a result, the higher the chances that it will become a commercially successful product. Global spending on cancer medications will reach $377 billion by 2027, followed by immunology, and diabetes will come in third with an estimated spending of about $169 billion What challenges arise when choosing pharmaceutical companies? you should also keep in mind that the larger the market, the higher the competition between medicines, as companies strive to grab as big a piece of the pie as possible. As a result, for drug sales to take off, they need to have significant competitive advantages over the "gold standard." These competitive advantages may include greater efficacy in treating a particular disease, less frequent administration, a more favorable safety profile, and a more convenient route of administration. So, in recent years, competition in the global spinal muscular atrophy treatment market has intensified. Spinal muscular atrophy is a genetic condition. Currently, three drugs have been approved to combat the disorder, including Biogen Inc.'s (BIIB) Spinraza, Roche/PTC Therapeutics, Inc.'s (PTCT) Evrysdi, and Novartis AG's (NVS) gene therapy Zolgensma. All three products have similar efficacy, but Evrysdi has a more favorable safety profile and is the more convenient route of administration, namely the oral route, which is reflected in its sales growth rate from year to year. The second pitfall is the company's pipeline of experimental drugs. I believe that financial market participants opening an investor presentation that presents a company's pipeline, especially if its market cap is below $5 billion, should also pay close attention to what stage of clinical trial activity its experimental drugs are in. if a pharmaceutical company has most of its product candidates in the early stages of development, this represents a significant risk because, in this case, institutional and retail investors are often overly optimistic about the prospects for the drugs' mechanisms of action and/or clinical data obtained in a small group of patients. Simultaneously, as is often the case, the higher the optimism, the less favorable the risk/reward profile. In most cases, the larger and more diverse the patient population, the weaker the efficacy of a drug relative to what was seen in Phase 1/2 clinical trials. This ultimately leads to a downward valuation of its likelihood of approval and casts doubt on its ability to take significant market share from approved medications. This may subsequently reduce the company's investment attractiveness, making it more difficult to attract financing for its operating activities. As a result, I recommend excluding any company that, instead of focusing its financial resources on the most promising product candidates, conducts multiple early-stage clinical trials to evaluate the efficacy of its experimental drugs. In my experience, the most successful pharmaceutical companies focus their efforts on bringing up to three product candidates to market and then reinvesting the revenue from their commercialization into developing the rest of the pipeline. The table below highlights the following parameters that I use to screen out the least promising companies. A third factor that investors, especially those new to the investment world, should consider is that large pharmaceutical companies are leaders in certain therapeutic areas, with a rich portfolio of patents covering various mechanisms of action and delivery methods of drugs, making it more difficult and more prolonged for smaller players to find product candidates that could potentially have the competitive advantages. So, Novo Nordisk A/S NYSE:NVO and Eli Lilly and Company NYSE:LLY have long been leaders in the global diabetes and weight loss drugs markets, and only very recently, they may be joined by Amgen Inc. NASDAQ:AMGN , Roche Holding, and several other companies 4/ Assessing a company's drug portfolio in comparison to competitors Evaluating the effectiveness, safety profile, and mechanism of action of a medication, as well as comparing clinical data with its competitors, takes a lot of time and effort. I provided examples of drugs and the most promising mechanisms of action in the obesity treatment market. Their manufacturers are Eli Lilly, Novo Nordisk, Roche Holding, Viking Therapeutics, Inc, Amgen, Pfizer, Altimmune, Inc, OPKO Health, Inc, Boehringer Ingelheim, and Zealand Pharma A/S 5/ When market exclusivity for a company's key medications ends Every financial market participant who is considering investing in pharmaceutical companies should consider the expiration time of key patents of medicines. Marketing exclusivity represents protection against the entry of a generic version and/or biosimilar of a branded drug into the market, thereby allowing the company to recoup the resources spent on its development and, in the event of its commercial success, also reinvest the money received to accelerate the development of the remaining product candidates. Where can you find information about patent expiration dates? All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange Book" section. let's take Eli Lilly as an example. Open the latest 10-K. Then, the CTRL + F combination opens the ability to find specific words in the document. I usually enter "Expiry Date" or "compound patent" to find the patent section.nvestors can also find information about patents on the FDA website. As an example, I enter "Mounjaro" in the top line, and a list of patents opens that protect Eli Lilly's blockbuster from the introduction of its generic versions onto the market.hen, clicking on "Appl. No." will open information about the submission date of the patent and when it will expire. 6/ Evaluating the impact of insider share transactions The next step in selecting the most interesting assets in the healthcare sector is to analyze Form-4s. The CEO, CFO, and other key members of the company's management buy or sell shares from time to time.I am only interested in analyzing purchases since, most often, sales by management are option exercises carried out to pay taxes. When management starts making large outright purchases of a company's shares, it can signal that it believes in its long-term growth potential.if more than two top managers buy a large block of shares within two weeks of each other, it significantly increases the likelihood of the company's stock price rising in the next two months from the moment of their transactions But as with everything, there are exceptions, such as in the case of OPKO Health, which is developing a long-acting oxyntomodulin analog for the treatment of obesity together with LeaderMed Group.Over the past 12 months, OPKO's management, especially CEO Phillip Frost, has purchased over 12 million shares. However, despite this, its stock price has fallen by 27% over the same period. I believe that the key reasons for the divergence between these two facts are investors' lack of confidence in Phillip Frost's ability to make the company profitable again, as well as its low cash reserves. Therefore, companies like OPKO Health have already been eliminated at the second step of selection using Seeking Alpha's screener. 7/ CEO Performance in Business Development The CEO plays a crucial role in the success of a pharmaceutical company since the pharmaceutical industry is highly dynamic, and the competition between Big Pharma is especially high, I advise readers to pay attention to the track record of the CEO, especially how he copes with force majeure situations, as well as how effective the R&D policy is carried out under his leadership. 8/ Identifying Entry and Exit Points for Long-Term Investments The eighth step is in addition to the information that was obtained in the previous steps, as well as the analysis of financial risks and various financial metrics of the company, including its net debt, maturity dates of bonds, historical revenue growth rates, EBIT, gross margin, I build a DCF model with the ultimate goal of determining the price target. it is necessary to conduct a technical analysis of them, as well as the main ETFs that include them. In my opinion, the key ETFs are the SPDR® S&P Biotech ETF AMEX:XBI , Fidelity Blue Chip Growth ETF AMEX:FBCG , iShares Biotechnology ETF NASDAQ:IBB , and VanEck Pharmaceutical ETF $PPH. The purpose of technical analysis is to determine the stop-loss level and entry points at which the risk/reward profile is most favorable. taking profit is not that easy cuz you must master your emotions and greed which damn hard 9/ Creating a Watchlist Based on Risk/Reward Ratio The purpose of which is to create a watchlist of the companies I have selected based on the previous steps. I make several lists of companies based on their market caps and also rank them according to risk/reward profile, that is, in the first place is the stock that I think has minimal risks and at the same time can bring the greatest potential profit. I also advise creating small notes on each company, which can include information about risks, support/resistance zones, dates of publication of clinical data, and any thoughts you have that will make your decision more conscious when opening a position “What’s your secret sauce for choosing pharma stocks?”
NYSE:NVOEducation
by moonypto
Spread triple top and BottomThe normal triple top has no gaps between the tops. The same philosophy applies in this pattern as in the triple top. In each case, the stock rises to a certain price level and is repelled two times. The third attempt at that price is successful by the stock’s moving through the level shown by a column of X’s exceeding the point of resistance. since the stock was repelled twice at that same level, there are apparently sell orders there. The reason is not important. What is important is that there are sellers at that particular level. The only way to know if demand can overtake the selling pressure is to see how the stock negotiates the level again. simply stated, if the stock is repelled again at this level of resistance, the sellers are still there. You need not know any more. If the stock exceeds that level, then demand has overcome the supply that previously caused it to reverse. This is why we always wait for a particular level to be exceeded before we make a long or short commitment in the stock. Friends, I conduct training in an individual format and in a limited number of students, since a large number will interfere with my trading! The training course includes : The Wyckoff Method Demark method VSA A trading method tailored to your psychotype Psychology of trading For details, write in a personal message I can also introduce you to my own unique indicators , of my own design Wykoff Zone (You determine the activity and zones of smart money and also gives buy and sell signals ) is a Demark indicator that has no analogues on the platform - since most of the indicator are far from the essence of the Demark technique and are too simplified , which violates the basics of the principle For investors, I can shift a 2-week lazy investor course where you can learn how to invest correctly and in which stocks + the tic-tac-toe method supplemented with your own developments taking into account the imbalance of supply and demand
NASDAQ:NUROEducation
by StudentWyckoff
How The Economy Affects The Stock Market ? How The Economy Affects The Stock Market ? There are many factors that affect how the stock market is doing, and whether it’s moving up or down: the political climate, social factors, interest rates, trends and shifts in what investors prefer. So how does the economy affect the stock market? If the general population feels as if the economy will soon be taking a turn for the worse, they tend to sell stock because bonds and treasuries offer a safer return. On the flip side, when people are feeling confident and optimistic about the economy, they tend to buy stock, taking more risk for greater reward. From a high-level approach, when people feel good about the economy, they tend to buy more stock. When things are happening in the world make them feel unsure, they will be more conservative, and might gravitate toward lower-risk investments such as bonds and Treasury bills. .
NSE:NIFTYEducation
by dsp21486
Why Is The Stock Market So Difficult To Predict?━━━━━━━━━━━━━ Let’s assume stock prices have been rising for several years. Investors realize that a correction will come and stock prices will tumble. What we don’t understand is what will trigger the selloff or exactly when it will occur. Therefore, some investors will sit on the sidelines holding cash, waiting for the opportune time to get in. Those who are willing to assume the risk may jump in because the return on cash is so low and it hurts to earn zero while watching stocks move higher. This begs a couple of key questions. If you’re on the sidelines, how will you know when to get in? If you’re already in, how will you know when it’s time to get out? If the stock market was predictable, these questions could easily be answered. However, it is not. There are actually three issues an investor should consider. The first is understanding the point at which stock prices are fairly valued. The second issue is the event that will cause a downturn
NSE:NIFTYEducation
by dsp21486
Barrelin 2.0 - Without Rules There Is Chaos!I am now about 4 weeks into sharing my #Barrelin pattern and associated trading strategy mostly on Twitter. In that time I have developed more regimented rules in hopes of automating the hunting if not the trades themselves. Here is the strategy as it stands today: ————- Entry 4hr close above 75% on RSI (14) Continuation Hold EMA (8) on 4hr close OR 1D close above 75% on RSI (14) (aka ‘Handoff to 1D’) AND Hold EMA (8) on 1D close OR 1W close above 75% on RSI (14) (aka ‘Handoff to 1W’) AND Hold EMA (8) on 1W close OR 1M close above 75% on RSI (14) (aka ‘Handoff to 1M’) AND Hold EMA (8) on 1M close Exit Close below EMA (8) on current timeframe that is #Barrelin ——— These handoffs are ideal but I am also starting to see, especially in stocks, the 4hr time frame is not only awkward with the limited trading but there are entries all the time on the higher timeframes without handoffs. The lower timeframes give an idea of momentum and personal preference can be used what timeframe to enter. This brings context to if you are “late” or not. I have posted over 650 tweets in those 4 weeks so searching through #Barrelin will help give a better idea of the ridiculous gains with it. Obviously there are fails and losers as well. I try to post these as well in order to see where the strategy can grow and evolve. The biggest evolution I am currently working on is a trailing take profit with a re-entry. Not sure how hard that part will be to automate but might as well fine tune the idea as much as possible and see what comes of it. Just with the shear volume of crypto and stocks I am following I have narrowed things down to just BTC pairs on Binance for crypto and no longer monitoring timeframes below the 4hr. It is personally impossible to still have any sort of life at that level. As for stocks I have been transformed into a fanboy!!! I can’t believe it. The gains seem to be more consistent and much more explosive - at least in the current atmosphere. There is still crypto popping off but I recommend crypto lovers to give my timeline a visit to see the crazy gains. I am loving the engagement with me and my strategy and I feel it is helping people which os my ultimate goal. I look forward to what the next 4 weeks brings as I try to scale this. Thanks for reading all the way through. Time is precious and I appreciate you investing some of your time here.
Education
by BarrelinChad
TradingView's Missing FeatureTradingView is an great platform. I am especially a fan of PineScript, the programming language that allows you to build custom indicators. But while TradingView's current features are great, I think this is something very important that is missing. Something that, were the developers of TradingView to implement it, would change it from a great platform to an EXCELLENT platform... And that feature is allowing users to screen stocks based on their scripts ! Why is this needed? There are many reasons: 1. Multi-timeframe analysis - The current TradingView screener has useful parameters, like finding stocks that are above their 20-day SMAs, but what if your strategy involves the values of indicators on a lower timeframe? For instance, what if you wanted to find stocks that are displaying a Golden Cross/Death Cross on the 1-hour chart? You can't do that currently, but it is easy in PineScript to tell if a stock has a Golden Cross or Death Cross simply by using the close series, or the security function to get the close from any timeframe. So if TradingView could implement a way to screen based on PineScript, this would make improved multi-timeframe analysis possible. 2. Published scripts - Perhaps you have read through some TradingView ideas and found an indicator you really like and want to use it as part of your trading strategy. But as we all know, not every stock -- or even every watchlist -- always provides an actionable signal all the time. So wouldn't it be great to be able to screen for stocks that are providing signals, even when those signals are based on indicators not included in TradingView's default list? 3. Personal scripts - Maybe you have developed a custom indicator of your own, and would like to find stocks that satisfy certain parameters based on it. Currently, you can't do that in TradingView. The closest solution is to build a 40-ticker watchlist, and then use the security function in a custom script to iteratively check each ticker against your condition. This is a decent workaround, but it still limits you to 40 tickers out of the hundreds of stocks on the market. So that leaves two other solutions - buy an API and make your own version of PineScript (not an easy, quick, convenient or affordable route, and one that requires a lot of programming skills) or... hope TradingView allows a new "screener" category for PineScript! 4. Greater flexibility - I have hinted at this in my other categories, but overall, screening based on PineScript would give the user far greater flexibility in his/her trading strategy. Maybe your strategy is complex, like "if condition A is met OR (condition B is met and condition C is met), go long," in which case, the existing TradingView screener would still require a lot of time-consuming and manual analysis to see if this either-or statement holds. But this is a few lines of code in PineScript! Users: So what do you think? Do you want to see the ability to include PineScript in TradingView screens? What sort of other powerful applications and strategies might you be able to implement if this feature were implemented? Let me know in the comments below and please give this post a "Like" if you want to encourage TradingView to implement PineScript-based screening! Moderators: If you could please pass this along to the developer team, it would be greatly appreciated! Thank you to the TradingView team for developing a great trading platform, and I look forward to continued development and additions!
AMEX:SPYEducation
by RandomUser2018
4
Algo makes me happy. ALGOs are here to stay. They obviously cannot be taken for granted. One thing I tell friends that purchase an Algo in the form of a Tradingview Script, is that it will help their trading decisions and confirm technical Analysis made by them. On my quest of finding a good Algorithm, not only for signals and accuracy, but supporting instruments, I came to Elite Signals Algo . Again, the goal if an Algo is to support your own Technical Analysis. With almost 80% accuracy, this instruments can help your decision making and maintain emotions on the control level. One of the coolest features is the auto drawing of Support and Resistance level. They are VERY accurate and combined with Candlestick pattern recognition, your day trading becomes very powerful. Is the Algo making me a lazy Trader? No, not at all. Its a supporting tool, same as any indicator. Are you interested in this great tool? Follow the link and send me any question you have. Enjoy your day trading! Disclaimer This idea does not constitute as financial advice. It is for educational purposes only. You can use the information from this post to make your own trading plan for the instruments discussed or other instruments. Trading carries a risk; a high percentage of retail traders lose money. Please keep this in mind when entering any trade. Stay safe.
CME_MINI:ESH2021Education
by Fondotoro
2
How I've traded Netflix this year. Morning traders. I just wanted to share how I've traded Netflix this year with the script I am using and the results I've gotten. Traded netflix only on an account with a well known CFD provider. £200 deposited and 76% gains on investments since March risking 1% per trade. This information is all provided by the back test data screen shot at bottom of the screen. As you will see from the idea screen I have provided details of how the script prompts me when to enter the market. I simply enter the market set my stop loss and take profit targets and let the trade play out. That easy! All the back test data backs the strategy up and takes away all the emotion of trading. Something we all struggle with as traders. Once the trade has played out I simply wait for the next signal alert and go again. This particular example is working the H1 and the example is taken from back in June and July. Currently I am in a live long position on this chart as we speak. So we will see how that plays out. For any more information on the script I am using please message me.
NASDAQ:NFLXEducation
by RichScott
How i know what stock have a good future in a crisis - TutorialHello, Some people asked in Telegram / PM how i know what stock will go up and which one should them short or long. I made a list about the different sectors of SPX 500 if its needed to go bear or bull on it. After you choose the sector you need to check the ADX of the coorporation, it need to be strong and always remember to chose the strongest coorporations of the sector that you selected. Here is the graphic: imgur.com You can see my last charts that i did green on almost all of them. Hope you liked and helped to you! Please follow me to keep doing daily analysis for free! Thank you so much! Regards,
NASDAQ:ZMEducation
by aleex5893
Pinterest is worth your interestPinterest #PINS is a fast-growing company with favorable demographics, the stock has dropped in price while outperforming expectations. Pinterest (PINS) debuted on the public markets less than a year ago at a price of $23.75. Since that time, Pinterest has dropped in price by a great percentage and do not thing for a moment that the coronavirus is to blame 🙂 The interesting part is that Pinterest has actually been profitable and has beaten earnings estimates in the last quarters. So why is it that Pinterest is dropping strongly, why? Because fundamentals are not that important when trading a supply and demand strategy. I’ve happened to read that some analysts are claiming that Pinterest #PINS is a buy for anyone with at least a two-year time horizon. Well, it may be that Pinterest stock will be revalued in two years time, but why buying Pinterest now and lock in part of your capital in a stock that is dropping like a rock reacting to super strong weekly supply zones? It makes no sense how some analysts and web sites are recommending buying Pinterest stock to hold it for two years when the stock is in a clear downtrend. Take a look at Pinterest #PINS supply and demand weekly timeframe analysis. There is a strong weekly supply around $25 per share, these supply zones act like magnets to price, a price level where there are a lot of interest by professional investors.
NYSE:PINSEducation
by AlfonsoMoreno
Roller Coaster Indicator Suite, Futures, Forex, Stocks & CryptoA look out our Roller Coaster Indicator suite using examples of forex, stocks, futures and cryptocurrency. Highlighting the need to understand trade size when comparing risk to reward. Also how to identify the best time frame to trade for the instruments that you trade. This Roller Coaster Indicator suite has an 83% win rate and uses a Stochastic/MACD Cross with special EMA points of control for entry and trade management. Again, they key is find the sweet spot with regards to the best time frame to trade for each currency pair, stock, futures contract or crypto instrument.
TVC:GOLDEducation
by xBratSoftwareSolutions
AMZN AMAZON Potential shorting opportunity When certain stocks have unfilled/un-traded areas (gaps) in the market, often the market going to revisit those areas later on. So these are areas can be targets for your trades. But in order to target those areas, we need a reason to get in. The most profitable/common method is waiting till the market exhaust and put a reversal signal. AMAZON is most likely to make a end to the BULL run and head back to fill those unfilled areas in the market. So waiting for a strong reversal signal or make another higher high with confluence to get SHORT. Good Luck Trading
NASDAQ:AMZNEducation
by sk_investments
Education post 6/100 – How to trade supply and demand zones? Supply and demand is a trading and price action concept that analyses how financial markets move and how buyers and sellers drive the price. On every price chart, there are certain price points where you can observe a sudden shift between the buyers and the sellers. Those areas are usually characterized by strong and immediate turning points, or an explosive breakout. We as traders call those areas supply and demand zones. It can pay off to know how to spot such areas because just like the concept or support and resistance, supply and demand areas can add an other layer of confluence to our trading and help us find better trades. Order absorption – why common trading knowledge is wrong The scenario below is something we all have seen hundreds of times. It shows the classic price behavior around a support level. Common trading wisdom tells you that with each touch of a price level, the support area becomes stronger. This couldn’t be further from the truth. What makes the price go down is an imbalance between buyers and sellers and there is more selling activity than buying going on. Each time the price reaches the support level, buyers enter the market and cause a bounce by outnumbering the sellers. Then, the price rises until sellers become interested again, outnumber the buyers and drive the price down. Although this is a very simplistic view, it explains how markets move. But each time the price makes it to the support level, there will be fewer buyers waiting because, at one point, all buyers who were interested in buying have executed their trades. This is called order absorption. The screenshot shows that price bounced less high with each “touch” and eventually it broke the support level once there were no more buyers left and only the absorbing sellers remained. When everyone has bought and when there are no buyers left, the support level will break and price falls until it reaches a price level where buyers will get interested again. MORE ON OUR WEBSITE...
Education
by GroundStoneHoldings
1
Education post 2/100 - How to trade triangle pattern?Symmetrical Triangle A symmetrical triangle is a chart formation where the slope of the price’s highs and the slope of the price’s lows converge together to a point where it looks like a triangle. What’s happening during this formation is that the market is making lower highs and higher lows. This means that neither the buyers nor the sellers are pushing the price far enough to make a clear trend. If this were a battle between the buyers and sellers, then this would be a draw. This is also a type of consolidation. In the chart above, we can see that neither the buyers nor the sellers could push the price in their direction. When this happens we get lower highs and higher lows. As these two slopes get closer to each other, it means that a breakout is getting near. We don’t know what direction the breakout will be, but we do know that the market will most likely break out. Eventually, one side of the market will give in. So how can we take advantage of this? Simple. We can place entry orders above the slope of the lower highs and below the slope of the higher lows. Since we already know that the price is going to break out, we can just hitch a ride in whatever direction the market moves. In this example, if we placed an entry order above the slope of the lower highs, we would’ve been taken along for a nice ride up. If you had placed another entry order below the slope of the higher lows, then you would cancel it as soon as the first order was hit.
Education
by GroundStoneHoldings